Condition: Spinocerebellar Ataxia Type 1 · Spinocerebellar Ataxia Type 3 · Huntington Disease · Sponsor: Vico Therapeutics B. V.
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.
This description comes directly from the study's public registry record.
Chief Medical Officer · +31 71 2036800 · info@vicotx.com
Always discuss trial participation with your own doctor first.
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Centre Hospitalier Universitaire dÁngers | Angers, France | Recruiting |
| CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology | Montpellier, France | Recruiting |
| Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris | Paris, France | Recruiting |
| Katholisches Klinikum Bochum | Bochum, Germany | Recruiting |
| Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE) | Bonn, Germany | Recruiting |
| Universitatsklinikum Essen - Neurologie | Essen, Germany | Recruiting |
| Universitatsklinikum Tübingen | Tübingen, Germany | Recruiting |
| Meir Medical Center | Kfar Saba, Israel | Recruiting |
| Sourmansky Medical Center | Tel Aviv, Israel | Recruiting |
| Leiden University Medical Center LUMC | Leiden, Netherlands | Recruiting |
| Radbout University Medical Centre | Nijmegen, Netherlands | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05822908